Methods of kidney function assessment in non-valvular atrial fibrillation in the era of new oral anticoagulants

European Journal of Internal Medicine

Volumn 25, Issue 6, 2014, Pages

  Andreu Cayuelas, José Manuel ^a   Marín, Francisco ^a   Flores Blanco, Pedro José ^a   García Alberola, Arcadio ^a   Manzano Fernández, Sergio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Atrial fibrillation; Cross sectional survey; Kidney function; New anticoagulants

Indexed keywords

ANTICOAGULANT AGENT; CREATININE; DABIGATRAN; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; BLEEDING; CONSENSUS; CREATININE CLEARANCE; CREATININE URINE LEVEL; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; LETTER; PHYSICIAN; PRIMARY MEDICAL CARE; RISK BENEFIT ANALYSIS; ATRIAL FIBRILLATION; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; FIBRINOLYTIC AGENTS; HUMANS; THROMBOEMBOLISM;

EID: 84903269039     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2014.02.007     Document Type: Letter

References (10)

1. O.M.P. Jolobe Accurate evaluation and monitoring of renal function will be crucial Eur J Intern Med 25 2014 e22
2. K.A. Wargo, E.H. Eiland III, W. Hamm, T.M. English, and H.M. Phillippe Comparison of the modification of diet in renal disease and Cockcroft-Gault equations for antimicrobial dosage adjustments Ann Pharmacother 40 2006 1248 1253
3. T.C. Dowling, E.S. Wang, L. Ferrucci, and J.D. Sorkin Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore longitudinal study on aging: impact on renal drug dosing Pharmacotherapy 33 2013 912 921
4. FDA Guidance for industry pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling Available from http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm204959.pdf (Accessed January 27, 2014)
5. NKDEP Chronic kidney disease and drug dosing: information for providers Available from http://nkdep.nih.gov/resources/ckd-drug-dosing-508.pdf 2010 (Accessed January 27, 2014)
6. EMA Summary of product characteristics: Pradaxa Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000829/WC500041059.pdf (Accessed January 27, 2014)
7. EMA Summary of product characteristics: Xarelto Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000944/WC500057108.pdf (Accessed January 27, 2014)
8. EMA Summary of product characteristics: Eliquis Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/002148/WC500107728.pdf (Accessed January 27, 2014)
9. M. Legrand, J. Mateo, A. Aribaud, S. Ginisty, P. Eftekhari, and P.T. Huy et al. The use of dabigatran in elderly patients Arch Intern Med 171 2011 1285 1286
10. J.E. Freshour, J.Q. Hudson, A.B. Stevens, and A.S. Franks Epistaxis associated with dabigatran in an elderly patient with reduced creatinine clearance Am J Health Syst Pharm 69 2012 1184 1186